Enzalutamide (Indenza) in Castration-resistant Prostate Cancer
Proven Effective in Multiple Stages of Disease Progression
Prostate Cancer?
The enlarged cell or the over-expressive cells in the prostate gland tends to cause prostate cancer.
Prostate Cancer: A Shifting Challenge
Prostate cancer is the prevalent cancer in men and is treated by surgery, radiation or hormone therapy.
However, the condition remains uncontrolled after treatment, leading to resistant prostate cancer.
What is Castration Resistant Prostate Cancer?
The cancer cell adapts to the changing environment and mutates to grow even in low levels of testosterone, reaching the castration state.
The cancer becomes resistant to hormone therapy and continues to grow, even after the removal of the testicles.
Treatments for Prostate Cancer
Hormone Deprivation Therapy
Testosterone promotes the growth of tumors. Hormone therapy effectively inhibits testosterone secretion.
Inhibiting androgen secretion shrinks the tumor and blocks cancer cell proliferation.
Enzalutamide (Indenza): A Game Changer in CRPC Treatment
Enzalutamide is a second-generation drug. It blocks the signaling pathway, directly blocking the androgen receptor or the response signal for cancer proliferation.
Enzalutamide Offers a Three-Step Blockade
- • Blocking testosterone binding to the androgen receptor.
- • Inhibiting the translocation of the androgen receptor.
- • Preventing androgen binding to DNA.
The first-generation androgen receptor blockers do not bind strongly.
Understanding the Paradoxical Role of Bicalutamide
Bicalutamide does not directly bind to the receptor; it is a competitive testosterone receptor antagonist that reduces its blocking efficacy. It acts as a partial agonist, which stimulates the androgen receptor without fully blocking it.
Why Enzalutamide is Superior in CRPC Management?
Compared to the first-generation androgen inhibitors, enzalutamide binds selectively to the testosterone receptors, potentially blocking the testosterone binding.
- • Selective blockade
- • Complete antagonist effects
- • Lower resistance
- • No agonist effect
- • Shuts down AR signaling entirely
- • Prolongs survival
- • Delays disease progression
- • Improves quality of life
- • Effective even after hormone resistance
Aprazer Healthcare – Advancing Cancer Care Globally
At Aprazer, we are committed to making essential healthcare accessible and affordable for all. We manufacture one of the largest ranges of high-quality anticancer medicines, including Indenza (Enzalutamide) for CRPC.
Global Reach
We are widely available in the global healthcare markets in CIS countries, Southeast Asia, Africa, and South America.
Why Aprazer?
- • World-class manufacturing infrastructure
- • Continuous research-driven innovation
- • Scientifically backed solutions
